Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37.25 USD | -0.53% | -7.34% | +29.88% |
05-09 | Wedbush Raises Price Target on Revolution Medicines to $46 From $42, Maintains Outperform Rating | MT |
05-08 | Revolution Medicines Q1 Net Loss Narrows | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+29.88% | 6.15B | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- RVMD Stock
- News Revolution Medicines, Inc.
- Transcript : Revolution Medicines, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 11